Effects of vaginally-administered oestriol on post-menopausal urogenital disorders: a cytohormonal study.
Forty post-menopausal women with urogenital disorders who were inpatients in the same geriatric hospital were treated with oestriol (E3) for 6 weeks. For the first 2 weeks 0.5 mg E3 (Leo AB, Sweden) was administered intravaginally every day. Over the following 4 weeks the patients received the same quantity either once or twice weekly as a maintenance dose. Oestrogen influence on the vaginal and urethral epithelium was assessed by means of the karyopyknotic index (KPI), while the degree of maturation of the vaginal epithelium was estimated visually. Urinary bacteria were cultivated. A pronounced and progressive rise in KPI was seen in both the vaginal and the urethral epithelium following daily E3 treatment. However, neither of the two maintenance dosages was sufficient to sustain the initial maturation of the vaginal and urethral epithelium induced by E3, since the KPI returned to pretreatment values within 4 weeks. The effect of E3 administration on the vaginal epithelium was overestimated by the visual assessment method. No changes were seen in urinary bacteria. Medroxyprogesterone acetate was given before and after E3 treatment. None of the women suffered from withdrawal bleeding.
Heimer
G M
GM
Department of Obstetrics and Gynaecology, Uppsala University, Akademiska sjukhuset, Sweden.
Englund
D E
DE
D000282:Administration, Intravaginal; D000368:Aged; D000369:Aged, 80 and over; D001284:Atrophy; D001437:Bacteriuria / Q000382:microbiology; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D004964:Estriol / Q000008:administration & dosage*; D005260:Female; D052776:Female Urogenital Diseases / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D014521:Urethra / Q000473:pathology; D014621:Vagina / Q000473:pathology
D004964:Estriol